XTX Topco Ltd Buys 36,989 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

XTX Topco Ltd grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 84.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 80,897 shares of the company's stock after buying an additional 36,989 shares during the period. XTX Topco Ltd owned 0.08% of Intellia Therapeutics worth $575,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics in the 4th quarter worth $25,000. Sterling Capital Management LLC increased its holdings in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after purchasing an additional 2,867 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of Intellia Therapeutics in the 4th quarter valued at about $43,000. Virtus ETF Advisers LLC increased its holdings in shares of Intellia Therapeutics by 47.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock valued at $61,000 after purchasing an additional 1,692 shares in the last quarter. Finally, 49 Wealth Management LLC purchased a new position in shares of Intellia Therapeutics in the 1st quarter valued at about $74,000. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NTLA traded down $0.67 during midday trading on Friday, hitting $10.79. 4,068,676 shares of the stock traded hands, compared to its average volume of 4,629,778. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $24.16. The firm has a market capitalization of $1.12 billion, a PE ratio of -2.30 and a beta of 2.31. The business's 50 day moving average price is $10.55 and its two-hundred day moving average price is $9.50.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping analysts' consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 54.90%. The company had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same period in the previous year, the firm earned ($1.52) EPS. Intellia Therapeutics's revenue was up 104.3% on a year-over-year basis. As a group, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analyst Ratings Changes

NTLA has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their price target on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a report on Tuesday, June 3rd. Guggenheim cut their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. Citigroup dropped their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. HC Wainwright dropped their price target on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Friday. Finally, Royal Bank Of Canada dropped their price target on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Friday. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $31.11.

Insiders Place Their Bets

In other news, EVP Edward J. Dulac III sold 7,462 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the sale, the executive vice president owned 106,062 shares in the company, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 12,534 shares of company stock valued at $153,837 in the last three months. Corporate insiders own 3.10% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.